Patent ExpiryThe patent of one of Lilly’s key products, Trulicity, will expire in 2027, which could significantly impact its revenue, as the product contributed 21% of group sales in 2023.
Regulatory ChallengesEMA's CHMP adopted a negative opinion for Leqembi and recommended the EC to not grant marketing authorization in the EU, which raises concerns about similar outcomes for other products under review.
Supply Chain IssuesComments at the JPM24 conference indicated that tirzep capacity will continue to be a bottleneck for the foreseeable future, potentially hindering growth.